Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Byooviz is a biosimilar of Lucentis, originally developed by Genentech and marketed outside the U.S. by Novartis.Italy's antitrust regulator has initiated an investigation into several pharmaceutical giants, including Novartis AG (NYSE:NVS) and Roche Holdings AG (OTC:RHHBY)-controlled Genentech, for allegedly restricting competition in the sale of an eye drug.
意大利反壟斷監管機構已經開始對包括諾華製藥（NYSE:NVS）和羅氏控制的吉納泰克在內的多個大型藥品製造商展開調查，涉嫌在眼科藥品銷售方面限制競爭。
The probe focuses on potential delays in the Italian market launch of Byooviz, a ranibizumab-based drug developed by Samsung Bioepis, due to coordinated strategies by these companies and their subsidiaries in Italy, the Netherlands, and the U.K.
該調查側重於三家公司及其在意大利、荷蘭和英國的子公司協同策略導致 Samsung Bioepis 開發的基於 ranibizumab 的藥物 Byooviz 在意大利市場上的潛在延遲。
Reuters noted that the Italian watchdog, supported by the finance police, carried out searches in Italy and the Netherlands, with assistance from the Dutch regulator.
路透社指出，得到金融警察支持的意大利監管機構在意大利和荷蘭進行搜查，並得到荷蘭監管機構的協助。
Byooviz is a biosimilar of Lucentis, originally developed by Genentech and marketed outside the U.S. by Novartis.
Byooviz 是美國外 Genentech 開發並由 Novartis 營銷的 Lucentis 生物相似藥。
Ranibizumab injections treat neovascular age-related macular degeneration and macular edema in the eye.
Ranibizumab 注射物可以治療眼部新生血管型年齡相關性黃斑變性和黃斑水腫。
The antitrust authority expressed concerns that the suspected delay could have limited drug availability and affected prices for patients, potentially impacting the cost-saving measures of the Italian national health services.
反壟斷機構表達了對涉嫌延遲可能導致限制藥物供應並影響患者藥物價格，可能影響意大利國家醫療服務的節約措施的擔憂。
Novartis is cooperating with the investigation, providing the requested information. In an emailed statement to Reuters, a company spokesperson emphasized that Novartis believes it has acted appropriately and in accordance with competition laws, always prioritizing patient interests.
諾華正在與調查合作，提供所請求的信息。該公司發言人在給路透社的一份電子郵件聲明中強調，諾華認爲其一直遵守競爭法並始終以患者利益爲優先。
Roche told Reuters it does not comment on regulatory or legal investigations but noted that biosimilar competition is a normal aspect of a treatment's lifecycle.
羅氏向路透社表示，我公司不對監管或法律調查發表評論，但指出生物相似物競爭是治療生命週期的正常方面。
The company highlighted the critical role of biosimilars in supporting healthcare systems' financial sustainability and fostering innovation.
該公司強調生物相似物在支持醫療系統的財務可持續性和促進創新方面扮演關鍵角色。
Samsung Bioepis also affirmed its full cooperation with the ongoing investigation, underscoring its commitment to transparency.
三星生物epis 特此確認其完全配合正在進行的調查，強調其對透明度的承諾。
Price Action: NVS shares are up 0.58% at $105.97 at the last check on Thursday.
股票行情：週四最後一次檢查時，NVS 股價上漲 0.58%，爲 105.97 美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本內容部分使用人工智能工具生成，並經Benzinga編輯審核發佈。
譯文內容由第三人軟體翻譯。